Merck sold $3.2 billion of its Covid oral antiviral treatment, driving first-quarter revenue growth

[ad_1]

Merck soundly beat Wall Street estimates for its top and bottom lines, reporting earnings of $2.14 per share on $15.9 billion in revenue.

[ad_2]

Source link